The company's principal activity is development of antineoplaston drugs currently being tested for use in the treatment of cancer. It also provides consulting services and is currently conducting approximately 36 fda-approved clinical trials. The company holds the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in antineoplaston drugs used in the treatment of cancer, once the drugs are approved for sale by the fda.
